Bob T. Li
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
-
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 99
- Lung Cancer Research Studies 31
- HER2/EGFR in Cancer Research 26
- Colorectal Cancer Treatments and Studies 17
- Cancer Immunotherapy and Biomarkers 14
- Peptidase Inhibition and Analysis 13
-
- Lung Cancer Treatments and Mutations 82
- Lung Cancer Diagnosis and Treatment 11
- Co-authors
- Jarushka NaidooKatja SchindlerDavid B. PageMario E. LacoutureLouise C. ConnellMichael A. PostowJedd D. WolchokMark G. Kris
- Journals
- Journal of Clinical Oncology (48 papers)Cancer Research (6 papers)Annals of Oncology (6 papers)JCO Precision Oncology (6 papers)Clinical Cancer Research (5 papers)
- Partner nations
- United StatesAustraliaJapan
In The Last Decade
Bob T. Li
138 papers receiving 4.6k citations
Hit Papers
Peers
Comparison fields: 5 of 137
- Oncology 3.3k
- Pulmonary and Respiratory Medicine 2.2k
- Cancer Research 773
- Immunology 501
- Radiology, Nuclear Medicine and Imaging 494
Countries citing papers authored by Bob T. Li
This map shows the geographic impact of Bob T. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bob T. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bob T. Li more than expected).
Fields of papers citing papers by Bob T. Li
This network shows the impact of papers produced by Bob T. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bob T. Li. The network helps show where Bob T. Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Bob T. Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 4 | |
| 6 | 2024 | 14 | |
| 7 | 2024 | 8 | |
| 8 | 2024 | 2 | |
| 9 | 2024 | 12 | |
| 10 | Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial Hit paper breakdown → | 2024 | 76 |
| 11 | 2023 | 28 | |
| 12 | 2023 | 19 | |
| 13 | 2023 | 23 | |
| 14 | 2021 | 8 | |
| 15 | 2019 | 41 | |
| 16 | 2019 | 35 | |
| 17 | 2018 | 188 | |
| 18 | 2018 | 230 | |
| 19 | 2015 | 221 | |
| 20 | 2015 | 212 |
About Bob T. Li
Bob T. Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Finance and Accounting, having authored 147 papers that have together received 4.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (82 papers), Cancer Genomics and Diagnostics (40 papers), Lung Cancer Research Studies (31 papers), HER2/EGFR in Cancer Research (26 papers), Colorectal Cancer Treatments and Studies (17 papers), Cancer Immunotherapy and Biomarkers (14 papers), Peptidase Inhibition and Analysis (13 papers) and Lung Cancer Diagnosis and Treatment (11 papers). The work is most often cited by research in Oncology (3.3k citations), Pulmonary and Respiratory Medicine (2.2k citations), Cancer Research (773 citations), Immunology (501 citations) and Radiology, Nuclear Medicine and Imaging (494 citations). Bob T. Li has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Jarushka Naidoo, Katja Schindler, David B. Page, Mario E. Lacouture, Louise C. Connell, Michael A. Postow, Jedd D. Wolchok, Mark G. Kris, Maria E. Arcila and Michael Offin. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, JCO Precision Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.